Biotech · Private company · Redwood City, CA, US
Afasci Inc
Track this companyFree. Adds Afasci Inc to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- AFA-281Phase 2 · Alcohol AbuseClinicalTrials.gov · fetched Nov 12, 2026
- AFA-281Phase 1 · Pain, NeuropathicClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use DisorderPHASE2 · NOT_YET_RECRUITING · started Oct 1, 2025ClinicalTrials.gov NCT06710431 · fetched Nov 12, 2026
- Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy VolunteersPHASE1 · COMPLETED · started Apr 11, 2023ClinicalTrials.gov NCT05547503 · fetched Nov 12, 2026
NIH awards3
- Accelerating the non-opioid analgesic AFA-281 clinical development with TABA-supported business developmentFiscal year 2025 · $50KNIH RePORTER 3R44NS132642-02S1 · fetched Nov 12, 2026
- Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic painFiscal year 2024 · $1.5MNIH RePORTER 5R44NS132642-02 · fetched Nov 12, 2026
- Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide HydrolaseFiscal year 2024 · $498.9KNIH RePORTER 5U43AA031391-02 · fetched Nov 12, 2026